COMP <GO>
GERN vs IRWD // RSI-14 & 200D SMA MOMENTUM
Geron Corporation (NASDAQ) VS. Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: GERN 1
— IRWD 4
▲ RSI-14 & 200D SMA MOMENTUM LEADER: IRWD
LAST: $0.89 (-5.47%) • MKT CAP: $607.9M
rsi-technicals
30.6
LAST: $3.50 (-3.31%) • MKT CAP: $598.2M
rsi-technicals
46.2
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GERN VS. IRWD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GERN | IRWD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.20% | 85.00% | -105.20 | IRWD | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 3.9x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -18.27% | 21.23% | -39.50 | IRWD | /fcf-yield <GO> |
| Operating Margin | — | 33.30% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 8.10% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | -15.70% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 0.20 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | IRWD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 30.6 | 46.2 | -15.60 | IRWD | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.2x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $607.9M | $598.2M | $9.7M | GERN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GERN REV | IRWD REV | GERN GROSS % | IRWD GROSS % | GERN FCF | IRWD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $296.2M | — | — | -$111.0M | $127.0M |
| FY 2024 | $0 | $351.4M | — | — | -$219.3M | $103.4M |
| FY 2023 | $237.0K | $442.7M | — | — | -$167.7M | $183.4M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GERN // BETA —
IRWD // BETA —